YU70494A - Inhibitori proteinske kinaze c - Google Patents

Inhibitori proteinske kinaze c

Info

Publication number
YU70494A
YU70494A YU70494A YU70494A YU70494A YU 70494 A YU70494 A YU 70494A YU 70494 A YU70494 A YU 70494A YU 70494 A YU70494 A YU 70494A YU 70494 A YU70494 A YU 70494A
Authority
YU
Yugoslavia
Prior art keywords
protein kinase
kinase inhibitors
indolemaleimide
mammals
chem
Prior art date
Application number
YU70494A
Other languages
English (en)
Other versions
YU49200B (sh
Inventor
W.F. Heath
M.R. Jirousek
J.H. Mcdonald
C.J. Rito
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of YU70494A publication Critical patent/YU70494A/sh
Publication of YU49200B publication Critical patent/YU49200B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

Pronalazak obezbeĐuje nove derivate bisindolmaleimid makrociklusa formule. Ovaj pronalazak dalje obezbeđuje dobijanje, farmaceutske formulacije i postupke za upotrebu radi inhibiranja proteinske kinaze C kod sisara.
YU70494A 1993-12-07 1994-12-02 Inhibitori proteinske kinaze c YU49200B (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US31697394A 1994-10-03 1994-10-03

Publications (2)

Publication Number Publication Date
YU70494A true YU70494A (sh) 1997-03-07
YU49200B YU49200B (sh) 2004-09-03

Family

ID=26859318

Family Applications (1)

Application Number Title Priority Date Filing Date
YU70494A YU49200B (sh) 1993-12-07 1994-12-02 Inhibitori proteinske kinaze c

Country Status (31)

Country Link
US (1) US5698578A (sh)
EP (1) EP0657458B1 (sh)
JP (2) JP3581731B2 (sh)
KR (1) KR100340159B1 (sh)
CN (2) CN1050844C (sh)
AT (1) ATE204579T1 (sh)
AU (1) AU687909B2 (sh)
BR (1) BR9404831A (sh)
CA (1) CA2137203C (sh)
CO (1) CO4340622A1 (sh)
CY (1) CY2413B1 (sh)
CZ (1) CZ291950B6 (sh)
DE (1) DE69428025T2 (sh)
DK (1) DK0657458T3 (sh)
ES (1) ES2162843T3 (sh)
FI (3) FI108138B (sh)
GR (1) GR3037087T3 (sh)
HK (1) HK1013827A1 (sh)
HU (1) HU219709B (sh)
IL (1) IL111850A (sh)
MY (1) MY125587A (sh)
NO (1) NO308798B1 (sh)
NZ (1) NZ270048A (sh)
PE (1) PE49195A1 (sh)
PL (1) PL182124B1 (sh)
PT (1) PT657458E (sh)
RU (1) RU2147304C1 (sh)
SG (1) SG63570A1 (sh)
TW (1) TW425397B (sh)
UA (1) UA44690C2 (sh)
YU (1) YU49200B (sh)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
DE69607443T2 (de) * 1995-11-20 2000-08-10 Lilly Co Eli Zwischenprodukte und ihre Anwendung für die Herstellung von N,N'-überbrückten Bisindolylmaleimiden
YU49315B (sh) * 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
US5919946A (en) * 1996-03-20 1999-07-06 Eli Lilly And Company Synthesis of indolylmaleimides
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
WO1997041127A1 (en) * 1996-05-01 1997-11-06 Eli Lilly And Company Halo-substituted protein kinase c inhibitors
BR9710706A (pt) * 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
AU4250697A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
JP2002514178A (ja) * 1996-08-30 2002-05-14 イーライ・リリー・アンド・カンパニー Ｈｉｖ感染が関与する中枢神経系疾患の治療用薬剤の製造を目的とするｐｋｃ阻害剤の使用
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
ATE423089T1 (de) * 1998-01-30 2009-03-15 Daiso Co Ltd Verfahren zur herstellung von butantriol- derivaten
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
ATE251624T1 (de) * 1998-03-13 2003-10-15 Univ British Columbia Granulatimide-derivate zur behandlung von krebs
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
DE60112611T2 (de) * 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE60217918T2 (de) * 2001-12-29 2007-11-15 Novo Nordisk A/S Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
CN100536850C (zh) 2003-08-08 2009-09-09 诺瓦提斯公司 包含星孢素的组合
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
EP1998776A4 (en) * 2006-03-10 2009-07-08 Janssen Pharmaceutica Nv MACRO-HETEROCYL COMPOUNDS CONTAINING PYRIDINE AS KINASE INHIBITORS
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
AU2011234644B2 (en) 2010-03-30 2014-07-17 Novartis Ag PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
TR201806682T4 (tr) 2012-11-29 2018-06-21 Novartis Ag Farmasötik kombinasyonlar.
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3317285B1 (en) 2015-07-02 2021-01-27 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
JP6817287B2 (ja) * 2015-07-21 2021-01-20 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キラルジアリール大環状分子及びその使用
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
PE20200700A1 (es) 2017-07-28 2020-06-23 Turning Point Therapeutics Inc Compuestos macrociclicos y usos de los mismos
PL3728271T3 (pl) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
WO1988007045A1 (en) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
EP0580812A1 (en) * 1991-04-11 1994-02-02 Schering Corporation Anti-tumor and anti-psoriatic agents
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
PL182124B1 (pl) 2001-11-30
EP0657458A1 (en) 1995-06-14
FI945706A (fi) 1995-06-08
CA2137203C (en) 2006-11-28
UA44690C2 (uk) 2002-03-15
IL111850A0 (en) 1995-03-15
EP0657458B1 (en) 2001-08-22
RU94042922A (ru) 1996-12-27
ES2162843T3 (es) 2002-01-16
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
NO308798B1 (no) 2000-10-30
NO944643D0 (no) 1994-12-02
FI108138B (fi) 2001-11-30
HK1013827A1 (en) 1999-09-10
US5698578A (en) 1997-12-16
FI945706A0 (fi) 1994-12-02
HUT71130A (en) 1995-11-28
ATE204579T1 (de) 2001-09-15
FI20000516A (fi) 2000-03-07
JP3581731B2 (ja) 2004-10-27
PT657458E (pt) 2002-02-28
SG63570A1 (en) 1999-03-30
CN1111247A (zh) 1995-11-08
HU9403468D0 (en) 1995-02-28
CA2137203A1 (en) 1995-06-08
DK0657458T3 (da) 2001-10-29
AU687909B2 (en) 1998-03-05
GR3037087T3 (en) 2002-01-31
CN1220266A (zh) 1999-06-23
CO4340622A1 (es) 1996-07-30
BR9404831A (pt) 1995-08-08
NZ270048A (en) 1996-11-26
CZ301894A3 (en) 1995-06-14
DE69428025D1 (de) 2001-09-27
CN1055089C (zh) 2000-08-02
MY125587A (en) 2006-08-30
CN1050844C (zh) 2000-03-29
JP2004269543A (ja) 2004-09-30
HU219709B (hu) 2001-06-28
KR950018010A (ko) 1995-07-22
CZ291950B6 (cs) 2003-06-18
JPH07215977A (ja) 1995-08-15
TW425397B (en) 2001-03-11
YU49200B (sh) 2004-09-03
IL111850A (en) 2002-11-10
RU2147304C1 (ru) 2000-04-10
AU7918894A (en) 1995-06-15
DE69428025T2 (de) 2002-05-29
NO944643L (no) 1995-06-08
KR100340159B1 (ko) 2002-11-23
FI20011109A (fi) 2001-05-28
CY2413B1 (en) 2004-11-12

Similar Documents

Publication Publication Date Title
YU70494A (sh) Inhibitori proteinske kinaze c
MX9707431A (es) Inhibidores de la proteina cinasa c.
MY118068A (en) Protein kinase c inhibitor
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
DK0916670T3 (da) Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
ECSP961937A (es) Inhibidor de proteina quinasa "c"